Journal of Leukemia & Lymphoma 2019;28(12):709-712

doi:10.3760/cma.j.issn.1009-9921.2019.12.002

Progress of immune checkpoint inhibitors in treatment of malignant lymphoma

Qingpei GUAN 1 ; Tingting ZHANG ; Xianhuo WANG ; Huilai ZHANG

Affiliations

+expand

Keywords

Lymphoma; Immune checkpoints; Immunotherapy; Programned death 1; Programmed death-ligand 1

Country

China

Language

Chinese

Abstract

The immune checkpoint inhibitors (ICI) represented by programmed death 1/programmed death ligand 1 (PD-1/PD-L1) antibody opened a new era of immunotherapy. However, PD-1/PD-L1 inhibitors have not been approved for indications in the field of malignant lymphoma except for classic Hodgkin lymphoma (cHL) and primary mediastinal large B-cell lymphoma. Researchers have actively explored different lymphoma subtypes with single drugs or combined therapy, and achieved certain effect initially. The latest advances of ICI in cHL, B-cell non-Hodgkin lymphoma and T-cell lymphoma and the management of immune-related adverse events are briefly introduced in this paper.